Beta Drugs Limited (NSE:BETA)

Market Cap	21.02B +15.4%
Revenue (ttm)	4.10B +10.1%
Net Income	455.86M +8.8%
EPS	44.31 +6.8%
Shares Out	10.14M
PE Ratio	46.79
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,698
Open	2,030.00
Previous Close	2,053.00
Day's Range	2,020.00 - 2,088.50
52-Week Range	990.10 - 2,807.90
Beta	-0.45
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Beta Drugs

Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 455
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BETA

Financial Performance

In fiscal year 2026, Beta Drugs's revenue was 3.85 billion, an increase of 6.20% compared to the previous year's 3.62 billion. Earnings were 414.83 million, a decrease of -2.21%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 2, 2026

Data Sources Report a data error